

Abraxane (for Maryland only)
Prior Authorization Request

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark administers the prescription benefit plan for the member identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Additional Demographic Information:

Patient Weight: _____ *kg*
Patient Height: _____ *ft* _____ *inches*

Criteria Questions:

1. What is the diagnosis?

<input type="checkbox"/> Breast cancer	<input type="checkbox"/> Epithelial ovarian cancer
<input type="checkbox"/> Non-small cell lung cancer (NSCLC)	<input type="checkbox"/> Fallopian tube cancer
<input type="checkbox"/> Pancreatic adenocarcinoma	<input type="checkbox"/> Primary peritoneal cancer
<input type="checkbox"/> Melanoma	<input type="checkbox"/> Other _____
2. What is the ICD-10 code? _____
3. Would the prescriber like to request an override of the step therapy requirement? Yes No *If No, skip to #6*
4. Has the member received the medication through a pharmacy or medical benefit within the past 180 days?
 Yes No **ACTION REQUIRED: Please provide documentation to substantiate the member had a prescription paid for within the past 180 days (i.e. PBM medication history, pharmacy receipt, EOB etc.)**
5. Is the medication effective in treating the member's condition?
 Yes No *Continue to #6 and complete this form in its entirety.*
6. How is the patient's disease classified?
Indicate all that apply

<input type="checkbox"/> Recurrent disease	<input type="checkbox"/> Metastatic disease
<input type="checkbox"/> Locally advanced disease	<input type="checkbox"/> Unresectable disease
<input type="checkbox"/> Persistent disease	<input type="checkbox"/> Other _____
7. In which clinical setting will Abraxane be used?

<input type="checkbox"/> As first line therapy	<input type="checkbox"/> As second line therapy
<input type="checkbox"/> As subsequent therapy	<input type="checkbox"/> As neoadjuvant therapy
<input type="checkbox"/> Other _____	
8. How will Abraxane be used (i.e. single agent, in combination with Gemzar)?
 _____ **Complete the following questions based on the patient's diagnosis.**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Abraxane CareFirst - 10/2016.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. © Registered trademark of CareFirst of Maryland, Inc.

Section A: Non-Small Cell Lung Cancer (NSCLC)

9. Is Abraxane being substituted for docetaxel or paclitaxel? Yes No
10. Has the patient experienced a hypersensitivity reaction after receiving docetaxel or paclitaxel despite premedication?
If Yes, no further questions Yes No
11. Are standard hypersensitivity premedications contraindicated for the patient?
If Yes, no further questions Yes No
12. *If clinical setting is subsequent therapy*, does the patient have any of the following tumor mutations?
 sensitizing epidermal growth factor receptor (EGFR)-positive
 anaplastic lymphoma kinase (ALK)-positive, *skip to #14*
 None of the above
13. Has the patient received prior EGFR inhibitor therapy [e.g., erlotinib (Tarceva), afatinib (Gilotrif), gefitinib (Iressa)]? *If Yes, no further questions* Yes No
14. Has the patient received prior ALK inhibitor therapy [e.g., crizotinib (Xalkori)]? Yes No

Section B: Melanoma

15. Will Abraxane be used for disease progression after prior systemic therapy? Yes No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)